European Association of Urology Guidelines on Muscle-invasive and Metastatic #BladderCancer : Summary of the 2025 Guidelines www.europeanurology.com/article/S030... Recommendations reflects regulatory changes, such as the removal of sacituzumab govitecan, and presents updated follow-up protocols

Zanidatamab plus palbociclib and fulvestrant in previously treated patients with HR+, HER2+ metastatic #BreastCancer www.thelancet.com/journals/lan... Results support further investigation of this chemotherapy-free triplet approach as a potential tx option @erikahamilton9.bsky.social

Advancing breast cancer treatment in the era of molecular diagnostics thebreastonline.com/article/S096... Recent advances in #BreastCancer treatment have shifted toward personalized, biomarker-driven approaches that leverage molecular diagnostics to guide therapy selection. ]

Duration and effect of neoadjuvant endocrine therapy on invasive tumor cellularity in hormone receptor-positive #BreastCancer link.springer.com/article/10.1... Findings suggest that prolonged NET may lead to more substantial tumor downstaging

Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a phase 1 trial OUT ON nature Cancer www.nature.com/articles/s43... Trial met its primary endpoints, supporting the feasibility and safety of this approach, and suggesting it warrants further investigation. #BladderCancer

NEWS FROM INDUSTRY Astra Zeneca reports that the POTOMAC Phase III trial demonstrated that adding 1yr durvalumab to standard Bacillus Calmette-Guérin induction and maintenance therapy significantly improved DGS in high-risk non-muscle-invasive #BladderCancer www.astrazeneca.com/media-centre...

Addition of zoledronic acid to enzalutamide and ADT in metastatic hormone-sensitive prostate cancer: BONENZA www.nature.com/articles/s41... Study confirmed that ZA did not enhance treatment efficacy in this setting, though WB-DW-MRI proved a reliable tool for monitoring bone metastasis response

PALMIRA: Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With HR+/HER 2– Advanced #BreastCancer ascopubs.org/doi/full/10.... Ultimately, the trial did not demonstrate a significant benefit of palbociclib rechallenge over ET alone in this setting.

2L Endocrine Therapy With or Without Palbociclib Rechallenge in HR+/Human Epidermal Growth Factor Receptor 2–Negative Advanced #BreastCancer: PALMIRA Trial ascopubs.org/doi/full/10.... Overall, palbociclib rechallenge did not significantly improve outcomes over ET alone in this setting.

Outcomes based on risk-adapted adjuvant therapy in postmenopausal women with early #BreastCancer 🇩🇰 sciencedirect.com/science/arti... Findings validate PSI as a useful tool for risk-adapted treatment allocation, supporting its role in sparing low-risk patients unnecessary chemotherapy

Stereotactic Body Radiation☢️Therapy Alone or in Combination with Immunotherapy in #KidneyCancer sciencedirect.com/science/arti... findings underscore the need for large, randomized trials to further evaluate SABR’s potential, particularly in metastatic settings.

Clinical characteristics & prognostic factors in pts with breast cancer and leptomeningeal metastases www.thebreastonline.com/article/S096... Highlight need for optimized treatment strategies & suggest clinicopathological factors can aid in selecting candidates for tx escalation or de-escalation

Selective Elimination of Breast Surgery for Invasive #BreastCancer out on JAMA Oncology jamanetwork.com/journals/jam... Findings suggest that in carefully selected cases, surgery may not be necessary, though further studies are needed to confirm this approach before changing standard practice.

Correlation analysis of invasive disease-free survival and OS in a real-world population of patients w/ HR+/HER2– early #BreastCancer acsjournals.onlinelibrary.wiley.com/doi/10.1002/... Results support iDFS as clinically meaningful & reliable 1ry endpoint assessing tx benefit in this setting

Treatment and Attrition Trends for Metastatic Clear Cell Renal Cell Carcinoma jamanetwork.com/journals/jam... Results revealed a shift from tyrosine kinase inhibitor (TKI) monotherapy, previously the most common first-line therapy, to ICI-based combinations following their approval. #KidneyCancer

Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial #BreastCancer thegreenjournal.com/article/S016...

Individualizing first-line treatment for advanced urothelial carcinoma: A favorable dilemma for patients and physicians sciencedirect.com/science/arti... Physicians and patients should engage in shared decision-making, considering the benefit-risk balance of each option. #BladderCancer

Histopathology based AI model predicts anti-angiogenic therapy response in renal cancer clinical trial nature.com/articles/s41... model showed strong correlation with the Angioscore and was effective in predicting AA response in real-world and clinical trial cohorts. #KidneyCancer

Body composition as a potential biomarker of recurrence risk in patients with triple-negative #BreastCancer link.springer.com/article/10.1... Findings suggest that VSR may serve as a stronger prognostic biomarker than BMI, with potential implications for future interventions aimed at reducing VSR

COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts ascopubs.org/doi/full/10.... The combination demonstrated clinical activity, particularly in cisplatin-eligible and chemotherapy-treated patients

Safety & Efficacy of Neoadjuvant Durvalumab + Gemcitabine/Cisplatin or Carboplatin in Patients W/ Operable High-Risk Upper Tract Urothelial Carcinoma ascopubs.org/doi/10.1200/... Although the primary endpoint was not met, the combination therapy showed promising downstaging effects #BladderCancer

The Germline and Somatic Origins of Prostate Cancer Heterogeneity out on CANCER DISCOVERY aacrjournals.org/cancerdiscov... The findings suggest that both high- and low-grade tumors originate from a common pre-malignant field, shaped by germline genomics and mutation timing. #ProstateCancer

The Germline and Somatic Origins of Prostate Cancer Heterogeneity out on CANCER DISCOVERY aacrjournals.org/cancerdiscov... The findings suggest that both high- and low-grade tumors originate from a common pre-malignant field, shaped by germline genomics and mutation timing. #ProstateCancer

STELLAR-304: a phase III study of zanzalintinib (XL092) plus nivolumab in advanced non-clear cell renal cell carcinoma www.tandfonline.com/doi/full/10.... This is the first phase III trial evaluating a TKI-ICI combination in nccRCC across multiple subtypes. #KidneyCancer

CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization aacrjournals.org/clincancerre... findings suggest that CA-125 could be a valuable biomarker for disease monitoring and treatment targeting in RMC. #KidneyCancer

OS analysis of Young-PEARL out on Lancet Oncology: Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic #BreastCancer www.sciencedirect.com/science/arti...

Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early #BreastCancer ascopubs.org/doi/10.1200/... Findings suggest that iDFS w/ sufficient follow-up is a reliable surrogate for OS in neoadjuvant RCTs, except in HR+ #BreastCancer @oncoalert.bsky.social 🚨

Endocrine Therapy💊 Interruption, Resumption, and Outcomes Associated With Pregnancy After Breast Cancer out on JAMA Oncology jamanetwork.com/journals/jam... Study highlights the need for better re-engagement of #BreastCancer survivors in guideline-based care after pregnancy🤰

Prolonged time to breast cancer surgery and the risk of metastasis https://buff.ly/3X8UgHN Study highlights importance of timely surgical treatment for #BreastCancer , as delaying surgery increases the risk of metastasis

Genetic testing in prostate cancer management: Considerations informing primary care acsjournals.onlinelibrary.wiley.com/doi/10.3322/... Review discusses the role of genetic testing in personalized PC care, the need for comprehensive family histories, and the integration of genetic counseling

Patient preferences for CDK4/6 inhibitor treatments in HR+/HER2− early #BreastCancer (Survey) link.springer.com/article/10.1... Findings suggest patient preferences may favor treatment profiles similar to ribociclib and will inform shared decision-making in selecting CDK4/6is for EBC treatment.

An insightful Abstract2Practice video by Our OncoAlert🚨 Colleague Dr. Petros Grivas🇺🇸 , where he breaks down the ARANOTE #ProstateCancer results👉 https://buff.ly/41146MS Find out how these results presented at ASCO #GU25 are applied in clinical practice.

Racial and ethnic disparities in conversion to mastectomy following lumpectomy out on #BreastCancer Research and Treatment link.springer.com/article/10.1... Racial disparities emerged, with White women experiencing a relative decrease in mastectomy conversions, while Black women saw an increase

Safety and efficacy of neoadjuvant durvalumab plus gemcitabine/cisplatin or carboplatin in patients with operable high-risk upper tract urothelial carcinoma: the iNDUCT trial out on JCO ascopubs.org/doi/abs/10.1...

Results of Stereotactic Body Radiation Therapy for Primary Renal Cell Carcinoma in a Large Multicenter Series out on European Urology Oncology sciencedirect.com/science/arti... These results suggest SBRT is an effective and well-tolerated option for inoperable RCC patients. #KidneyCancer

Circulating immune biomarkers correlating with response in patients with metastatic renal cell carcinoma on immunotherapy insight.jci.org/articles/vie... #kidneyCancer Findings suggest that macrophage activation and the innate immune response play crucial roles in ICI efficacy #KidneyCancer

A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced TNBC #BreastCancer link.springer.com/article/10.1... The study found NO🚫 improvement in progression-free survival (PFS) or response rate with the addition of mifepristone @oncoalert.bsky.social 🚨

Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a US Food and Drug Administration pooled analysis academic.oup.com/jnci/article... Pooled analysis assessed the clinical outcomes of patients with metastatic renal cell carcinoma (mRCC)

The significance of isolated de novo red patches in the bladder in patients referred with suspected urinary tract cancer: IDENTIFY study bjui-journals.onlinelibrary.wiley.com/doi/10.1002/... Highlights need for more selective biopsy approaches, especially considering patient age and risk factors

Annual versus less frequent mammographic surveillance in people with #BreastCancer aged 50 years and older in the UK (Mammo-50) www.thelancet.com/journals/lan... The Mammo-50 trial, Supporting the consideration of less frequent mammography for this population.